Cancer Brain Metastasis: Molecular Mechanisms and Therapeutic Strategies

Overview

Journal Mol Biomed

Specialties Biomedical Engineering
General Medicine
Pathology

Date 2025 Feb 25

PMID 39998776

Authors

Yu Lu

Yunhang Huang

Chenyan Zhu

Zhidan Li

Bin Zhang

Hui Sheng

Haotai Li

Xixi Liu

Zhongwen Xu

Yi Wen

Jing Zhang

Liguo Zhang

Affiliations

Soon will be listed here.

Abstract

Brain metastases (BMs) are the most common intracranial tumors in adults and the major cause of cancer-related morbidity and mortality. The occurrence of BMs varies according to the type of primary tumors with most frequence in lung cancer, melanoma and breast cancer. Among of them, lung cancer has been reported to have a higher risk of BMs than other types of cancers with 40 ~ 50% of such patients will develop BMs during the course of disease. BMs lead to many neurological complications and result in a poor quality of life and short life span. Although the treatment strategies were improved for brain tumors in the past decades, the prognosis of BMs patients is grim. Poorly understanding of the molecular and cellular characteristics of BMs and the complicated interaction with brain microenvironment are the major reasons for the dismal prognosis of BM patients. Recent studies have enhanced understanding of the mechanisms of BMs. The newly identified potential therapeutic targets and the advanced therapeutic strategies have brought light for a better cure of BMs. In this review, we summarized the mechanisms of BMs during the metastatic course, the molecular and cellular landscapes of BMs, and the advances of novel drug delivery systems for overcoming the obstruction of blood-brain barrier (BBB). We further discussed the challenges of the emerging therapeutic strategies, such as synergistic approach of combining targeted therapy with immunotherapy, which will provide vital clues for realizing the precise and personalized medicine for BM patients in the future.

References

Bernal G, LaRiviere M, Mansour N, Pytel P, Cahill K, Voce D . Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma. Nanomedicine. 2013; 10(1):149-57. PMC: 3871979. DOI: 10.1016/j.nano.2013.07.003. View

Angeli E, Bousquet G . Brain Metastasis Treatment: The Place of Tyrosine Kinase Inhibitors and How to Facilitate Their Diffusion across the Blood-Brain Barrier. Pharmaceutics. 2021; 13(9). PMC: 8468523. DOI: 10.3390/pharmaceutics13091446. View

Vanlandewijck M, He L, Mae M, Andrae J, Ando K, Del Gaudio F . A molecular atlas of cell types and zonation in the brain vasculature. Nature. 2018; 554(7693):475-480. DOI: 10.1038/nature25739. View

Shaw A, Bauer T, de Marinis F, Felip E, Goto Y, Liu G . First-Line Lorlatinib or Crizotinib in Advanced -Positive Lung Cancer. N Engl J Med. 2020; 383(21):2018-2029. DOI: 10.1056/NEJMoa2027187. View

Pellerino A, Bruno F, Ruda R, Soffietti R . Systemic Therapy for Lung Cancer Brain Metastases. Curr Treat Options Oncol. 2021; 22(12):110. DOI: 10.1007/s11864-021-00911-7. View

Karre K . Express yourself or die: peptides, MHC molecules, and NK cells. Science. 1995; 267(5200):978-9. DOI: 10.1126/science.7863341. View

Arrieta O, Barron F, Padilla M, Aviles-Salas A, Ramirez-Tirado L, Arguelles Jimenez M . Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019; 5(11):e192553. PMC: 6735425. DOI: 10.1001/jamaoncol.2019.2553. View

Liu L, Mayes P, Eastman S, Shi H, Yadavilli S, Zhang T . The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res. 2015; 21(7):1639-51. DOI: 10.1158/1078-0432.CCR-14-2339. View

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View

10.

Halasz L, Uno H, Hughes M, DAmico T, Dexter E, Edge S . Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer. Cancer. 2016; 122(13):2091-100. PMC: 4911286. DOI: 10.1002/cncr.30009. View

11.

Hu H, Xu Z, Zhu Q, Liu X, Jiang S, Zheng J . Brain Metastases Status and Immunotherapy Efficacy in Advanced Lung Cancer: A Systematic Review and Meta-Analysis. Front Immunol. 2021; 12:669398. PMC: 8316922. DOI: 10.3389/fimmu.2021.669398. View

12.

Steeg P . The blood-tumour barrier in cancer biology and therapy. Nat Rev Clin Oncol. 2021; 18(11):696-714. DOI: 10.1038/s41571-021-00529-6. View

13.

Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert W, Goldbrunner R, Herms J . Real-time imaging reveals the single steps of brain metastasis formation. Nat Med. 2009; 16(1):116-22. DOI: 10.1038/nm.2072. View

14.

Kumthekar P, Tang S, Brenner A, Kesari S, Piccioni D, Anders C . ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. Clin Cancer Res. 2020; 26(12):2789-2799. DOI: 10.1158/1078-0432.CCR-19-3258. View

15.

Fuchs J, Fruh M, Papachristofilou A, Bubendorf L, Hauptle P, Jost L . Resection of isolated brain metastases in non-small cell lung cancer (NSCLC) patients - evaluation of outcome and prognostic factors: A retrospective multicenter study. PLoS One. 2021; 16(6):e0253601. PMC: 8238224. DOI: 10.1371/journal.pone.0253601. View

16.

Yang Y, Deng L, Yang Y, Zhang T, Wu Y, Wang L . Efficacy and Safety of Combined Brain Radiotherapy and Immunotherapy in Non-Small-Cell Lung Cancer With Brain Metastases: A Systematic Review and Meta-Analysis. Clin Lung Cancer. 2021; 23(2):95-107. DOI: 10.1016/j.cllc.2021.06.009. View

17.

Abbott N, Patabendige A, Dolman D, Yusof S, Begley D . Structure and function of the blood-brain barrier. Neurobiol Dis. 2009; 37(1):13-25. DOI: 10.1016/j.nbd.2009.07.030. View

18.

Nakamura K, Smyth M . Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol Immunol. 2019; 17(1):1-12. PMC: 6952382. DOI: 10.1038/s41423-019-0306-1. View

19.

Singh Achrol A, Rennert R, Anders C, Soffietti R, Ahluwalia M, Nayak L . Brain metastases. Nat Rev Dis Primers. 2019; 5(1):5. DOI: 10.1038/s41572-018-0055-y. View

20.

Viani G, Gouveia A, Louie A, Moraes F . Stereotactic radiosurgery for brain metastases from small cell lung cancer without prior whole-brain radiotherapy: A meta-analysis. Radiother Oncol. 2021; 162:45-51. DOI: 10.1016/j.radonc.2021.06.026. View